I-DireCT SIGNED
Immune DIREcted and Cancer-selective immunoTherapy
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0I-DireCT project word cloud
Explore the words cloud of the I-DireCT project. It provides you a very rough idea of what is the project "I-DireCT" about.
Project "I-DireCT" data sheet
The following table provides information about the project.
| Coordinator |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 2˙533˙358 € |
| EC max contribution | 2˙533˙358 € (100%) |
| Programme |
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers) |
| Code Call | H2020-MSCA-ITN-2018 |
| Funding Scheme | MSCA-ITN-EID |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-01-01 to 2022-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ACADEMISCH ZIEKENHUIS GRONINGEN | NL (GRONINGEN) | coordinator | 929˙669.00 |
| 2 | INOCURE SRO | CZ (PRAHA) | participant | 587˙178.00 |
| 3 | Surflay Nanotec GmbH | DE (BERLIN) | participant | 505˙576.00 |
| 4 | UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | DE (WURZBURG) | participant | 379˙182.00 |
| 5 | KAHR MEDICAL LTD | IL (JERUSALEM) | participant | 131˙750.00 |
Map
Project objective
I-DireCT is a European Industrial Doctorate (EID) training network designed to provide training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy in a carefully integrated academic and inter-sectoral programme. Hereby, we aim to develop next-generation immunotherapeutics and deliver a set of early stage researchers uniquely qualified for a career in academia and/or industry.
Current immunomodulatory antibodies that target pivotal immune checkpoints have revolutionized the field of oncology. However, off-tumor activity limits their application. The objective of I-Direct is to address this issue by 1. developing innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects and 2. developing optimized delivery systems to ensure optimal timed release of bio-active drug. Hereto, I-DireCT combines state-of-the-art industrial design of nanotech-based drug formulations with innovative academic and industrial immunotherapeutic concepts into the next-generation of cancer immunotherapeutics.
At the core of I-DireCT is its training objective to offer a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development.
Industrial partners are central to the programme and provide pivotal inter-sectoral expertise on how to translate scientific discoveries into commercial reality, with each ESR being appointed at an inter-sectoral partner for 18 months, as well as through additional secondments. Further, I-Direct will enable long-term multi-disciplinary research and fosters bilateral co-operations between academia and industry.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "I-DIRECT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "I-DIRECT" are provided by the European Opendata Portal: CORDIS opendata.
